1. Johnson & Johnson acquired Intra-Cellular Therapies to enhance its Innovative Medicine division. 2. This acquisition aims to advance care for neuropsychiatric and neurodegenerative disorders.
Acquisitions typically enhance long-term growth prospects, especially in therapeutic areas like neurodegeneration. Historical examples include Pfizer's acquisition of Wyeth, which boosted its product pipeline.
This acquisition strengthens JNJ's position in the neurotherapeutics market, which is expected to grow significantly, thus increasing future revenues.
Such acquisitions can take time to integrate and yield results, impacting JNJ positively in the future as new treatments are developed.